NEWS

During October’s Intellectual Property Month, WWFH’s Executive Director Dan Leonard sat down with Laura Schoppe of Tech Pipeline  for a timely conversation about the future of American innovation. With China's biopharmaceutical sector gaining ground and policy challenges mounting at home, Laura's insights come at a critical moment. Drawing on her experience in academic technology transfer and biopharmaceutical innovation, Laura offers a nuanced look at both the opportunities

In recognition of Intellectual Property (IP) Month, We Work For Health 's Executive Director Dan Leonard sat down with Stephen Ezell of the Information Technology and Innovation Foundation (ITIF) to explore the state of America’s innovation ecosystem. Their conversation covered pressing topics such as rising competitive challenges from China and how misguided policy choices could impact the U.S.’s global standing for generations. Ezell, who directs ITIF’s Center for Life Sci

Last week, the Senate Judiciary Committee’s Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act  (PERA) , which would bring much-needed clarity to the patent system that is essential for the United States maintaining its global leadership in the life sciences.   October is Intellectual Property Month, and We Work For Health is continuing to call on policymakers to prioritize meaningful reforms and modernize the intellectual property

A Hong Kong-based healthcare expert recently warned that China's biotechnology sector has achieved such rapid advancement and cost advantages that it may fundamentally reshape the global pharmaceutical landscape and potentially displace the United States as the world’s innovator of new cures. Cui Cui, managing director and head of Asia healthcare research at Jefferies, recently spoke to Endpoints News about the dramatic transformation of China’s life sciences sector and the

There is yet another metric depicting how China is aggressively readying itself to challenge, and potentially surpass,...

America's biopharmaceutical sector is delivering unprecedented investment in domestic innovation and manufacturing capacity. In 2025...

Former FDA commissioner Scott Gottlieb recently appeared on an Endpoints News video series to share insight  into China's rapid ascent in...

China’s life science footprint once functioned as little more than a factory on the global stage. It supplied high-volume generics and...

The House Energy and Commerce Subcommittee on Health recently held a hearing, Examining Policies to Enhance Seniors’ Access to...

By: Dan Leonard, Executive Director, We Work For Health The decades-long partnership between the federal government, research-focused...

The Most Favored Nation (MFN) drug pricing policy proposal remains an administration focus since a May executive order . Most recently,...

Together with the Council for Innovation Promotion, We Work For Health recently hosted a roundtable discussion focused on the pivotal...

By: Dan Leonard, Executive Director, We Work For Health Kansas is both a driver and a beneficiary of the most sustained period of growth...

Roundtable Highlights How Strong IP Protections Drive Breakthroughs and Benefit Patients RALEIGH, NC (August 12, 2025) — On Tuesday,...

By: Tom Kowalski, Co-Chair, We Work For Health Recent efforts to revive the so-called “Most Favored Nation” (MFN) drug pricing policy...

The Bayh-Dole Act of 1980 enables universities to retain intellectual property rights to discoveries made with federal funding, spurring...

While some in Washington are proposing damaging drug pricing policies, including “Most Favored Nation,” China is gaining ground in...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health What do North Carolina’s incredible universities have in common, in...

A common depiction of a U.S. biopharmaceutical industry worker shows someone working alone in a sterile lab environment. They wear a...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health Smart policymaking and American ingenuity have combined to create an...

American innovation has long been the envy of the world, built on a foundation of strong intellectual property protections,...

By Dan Leonard, Executive Director, We Work For Health Global innovation is a long-distance race. For decades, the United States has led...

WASHINGTON, D.C. (May 12, 2025) — We Work For Health released the following statement in response to the executive order signed Monday...

By: Dan Leonard, Executive Director, We Work For Health The Administration’s latest proposal to revive the Most Favored Nation (MFN) drug...

WASHINGTON, D.C. (May 5, 2025) — We Work For Health released the following statement in response to reports around foreign reference...

By Dan Leonard, Executive Director, WWFH The Inflation Reduction Act (IRA), signed into law in August 2022, contains a healthcare...

This Saturday, we observe World Intellectual Property Day , a moment to reflect on how intellectual property (IP) rights enable...

We Work For Health recently hosted a Congressional briefing about the IRA "pill penalty" and the importance of passing the Ensuring...

By Tom Kowalski, WWFH Co-Chair Chronic disease has contributed to declining life expectancy in the United States , a disturbing pattern...

We Work For Health released the following statement on the Trump Administration’s April 15 executive order regarding the Inflation...

Small-molecule drug investment has fallen 68%—and 74% for diseases mainly affecting Medicare patients—since the IRA was introduced FOR...

The lead sponsors of the Ensuring Pathways to Innovative Cures (EPIC) Act addressed a room full of Congressional office employees and...

Learn about the Inflation Reduction Act—and how it’s threatening America’s biopharmaceutical ecosystem and our nation’s Medicare-aged...

Innovation often comes in increments. The first smartphones could not record video or take front-facing photos, and there certainly was...

A new report highlights the significant investments and economic impact generated by clinical trials funded by the biopharmaceutical...

Legislation would address the “pill penalty” and strengthen U.S. leadership in pharmaceutical innovation. WASHINGTON, D.C. (March 6,...

Healthcare costs continue to be a significant concern for Americans. While policies like government price controls under the Inflation...

Small-molecule drugs, which typically come in pill or tablet form, have long been the backbone of modern medicine, treating everything...

Bipartisan legislation would correct the IRA’s “pill penalty,” which will have a chilling effect on the prescription drug ecosystem...

We Work For Health Executive Director Dan Leonard's recently wrote a letter to the White House, encouraging a pause in the implementation...

FOR IMMEDIATE RELEASE JAN. 17, 2025   WASHINGTON, DC (Jan. 17, 2025) – The Centers for Medicare and Medicaid Services’ (CMS) announcement...

Throughout 2024, the pharmaceutical industry announced $31 billion  in confirmed investment commitments across the United States,...

Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment,...

At We Work For Health (WWFH), our commitment to fostering health equity across the nation goes beyond advocacy—it extends to tangible,...

The biopharmaceutical industry is the backbone of America's innovative economy, supporting more than 4.9 million jobs across the United...

We Work For Health Executive Director Dan Leonard released the following statement in support of recently introduced legislation that...